Verastem, Inc. (VSTM) is an oncology biopharmaceutical company focused on therapies for RAS and MAPK pathway-driven cancers. It is a stock, not an exchange-traded fund, so this analysis centers on equity analyst price targets rather than fund holdings or index methodology.
Reviewing current, attributable analyst targets yields nine valid figures. The most recent revisions cluster in a range of roughly $13 to $24. At the high end, BTIG carries a $24 target, followed by Alliance Global Partners at $22 and H.C. Wainwright at $20. In the middle, RBC Capital sits at $18, Guggenheim and Benchmark at $14, and Jefferies and Mizuho at $13. The arithmetic mean of these nine targets is about $17.10, which rounds to a $17 central target.
Consensus leans decidedly bullish, with virtually all covering firms at Buy or Strong Buy. That said, the spread between $13 and $24 reflects genuine disagreement about how quickly the commercial launch will translate into durable value. Analysts emphasize the FDA approval of the avutometinib plus defactinib combination for KRAS-mutant recurrent low-grade serous ovarian cancer as the central thesis, while lower targets embed more caution around competition and cash burn.
Shares recently traded near $8.20, having pulled back roughly 10% in a single session after third-quarter results and then stabilizing. Reaching $17 would require an increase of approximately 108%, a very large move that is consistent with the wide dispersion in analyst targets rather than a near-term repricing.
The path depends on execution rather than a single valuation re-rating. Verastem reported third-quarter revenue of about $24 million against a GAAP net loss of roughly $75 million, reflecting the early stage of its commercial rollout. Because the company remains unprofitable, conventional P/E (price-to-earnings) valuation does not apply, and the stock is driven primarily by launch trajectory, clinical catalysts, and sentiment around the KRAS pipeline.
The clearest support is commercial traction. The avutometinib and defactinib combination gives Verastem a first-to-market position in KRAS-mutant low-grade serous ovarian cancer, a niche with limited competition and meaningful unmet need. Revenue is ramping from a small base, with full-year 2026 estimates pointing to a sharp year-over-year increase.
A second pillar is the pipeline, particularly VS-7375 for KRAS G12D-mutant solid tumors, which analysts view as optionality beyond the initial launch. Positive clinical readouts in a large, historically difficult-to-drug target could justify materially higher valuation. A strong cash position and a consensus of Buy ratings also provide a supportive backdrop.
The principal obstacle is profitability. Verastem continues to post substantial net losses, and reaching $17 implies a market capitalization far above today's level without the earnings support that typically anchors such valuations. If the launch ramps more slowly than modeled, or if gross-to-net dynamics and competition compress the opportunity, the stock could struggle to re-rate.
The KRAS space is also becoming crowded, with larger competitors advancing programs across multiple mutations. Pipeline setbacks for VS-7375, dilution from future financings, and general risk-off sentiment in small-cap biotechnology could each pressure the shares. Several analysts trimmed targets in 2026, reflecting exactly these concerns.
The stock's 52-week range runs from roughly $3.43 to about $10.82. The recent pullback left shares below the $10 area, which now acts as overhead resistance, while the single-digit $8 zone has functioned as a short-term support area. A durable move toward the $17 target would first require reclaiming and holding above the prior highs near $10.82, a level that has repeatedly capped rallies.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch quarterly revenue and launch metrics for the avutometinib and defactinib combination, updates on the VS-7375 program, and any changes to cash runway or financing plans. Data readouts in the KRAS G12D program, analyst target revisions, and broader biotech risk appetite are the most likely near-term drivers.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis shift. Traders can use these signals to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone. For investors tracking a volatile name like Verastem, automated signal monitoring can help flag turning points as they develop.
The $17 central target for Verastem (VSTM) is the arithmetic mean of nine analyst price targets ranging from roughly $13 to $24. Because the stock trades near $8.20, the required move of about 108% is very large, and the wide target range underscores meaningful disagreement about execution. Commercial momentum for the avutometinib and defactinib combination and the KRAS pipeline are the strongest supports, while persistent losses, a competitive oncology landscape, and dilution risk are the primary obstacles. Whether the shares approach $17 will depend on launch trajectory, clinical data, and analyst revisions in the quarters ahead, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with ZYME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then ZYME could also see price increases.
| Ticker / NAME | Correlation To VSTM | 1D Price Change % | ||
|---|---|---|---|---|
| VSTM | 100% | -7.73% | ||
| ZYME - VSTM | 44% Loosely correlated | -2.68% | ||
| SRPT - VSTM | 40% Loosely correlated | -5.93% | ||
| MLYS - VSTM | 40% Loosely correlated | -3.53% | ||
| ARVN - VSTM | 40% Loosely correlated | -4.15% | ||
| TSHA - VSTM | 39% Loosely correlated | -1.33% | ||
More | ||||